The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis.

ABSTRACT:

Aims

To investigate the impact of baseline 1,5-anhydroglucitol on the treatment effect of basal-bolus therapy in people with Type 2 diabetes.

Methods

Post hoc analysis of onset 3, an 18-week, randomized, phase 3 trial evaluating the efficacy and safety of fast-acting insulin aspart in basal-bolus therapy (n = 116) vs. basal insulin-only therapy (n = 120) in people with Type 2 diabetes. The estimated treatment difference in change from baseline in HbA_1c was investigated for different cut-off values of baseline 1,5-anhydroglucitol (2, 3, 4, 5 and 6 μg/ml).

Results

The estimated treatment difference in change from baseline in HbA_1c between basal-bolus therapy and basal insulin-only therapy was statistically significantly greater in participants with

SUBMITTER: Heller S 

PROVIDER: S-EPMC6099439 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature